Loading
A phase 1/2 trial of Saruparib, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer and prostate cancer, run by AstraZeneca, active and no longer recruiting.
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT04644068 by AstraZeneca, with 702 participants enrolled, started 2020-11-12 and due to reach its primary completion in 2027-05-28. Interventions recorded: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd. Conditions listed: Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Datopotamab deruxtecan, AstraZeneca, Carboplatin, Ovarian cancer.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Saruparib, AstraZeneca, Prostate cancer.
Shares Saruparib, AstraZeneca, Ovarian cancer, Small-cell lung cancer.
Shares Datopotamab deruxtecan, AstraZeneca, Carboplatin, Small-cell lung cancer.
Shares Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Trastuzumab deruxtecan, AstraZeneca, Carboplatin, Small-cell lung cancer.
Shares Datopotamab deruxtecan, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.